Sangamo Therapeutics, Inc.
SGMOQ
Other OTC0.16
USD
+0.00
- -
CIK
0001001233
ISIN
US8006771062
CUSIP
800677106
Return %
Stock
S&P500
1Y
-69.62
18.65
3Y
-83.23
71.44
5Y
-98.39
70.60
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Alexander D. Macrae
- Full Time Employees
- 142
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 501 Canal Blvd Richmond CA United States of America 94804
- IPO Date
- Apr 6, 2000
- CIK
- 0001001233
- Website
- sangamo.com
- Similar Companies
- Business
- Sangamo Therapeutics, Inc. is a genomic medicine company focused on translating ground-breaking science into therapeutic solutions across gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing and genome regulation, with a particular emphasis on neurology-driven programs alongside hematology/rare diseases and broader genomic technologies; it operates through internal development and strategic partnerships to advance a diversified pipeline addressing serious diseases. The company leverages zinc finger protein-based platforms (ZFPs) for gene regulation and editing, capsid discovery for delivery, and related regulatory/epigenetic technologies to create genomic medicines that aim to transform patient outcomes. Sangamo applies its platforms to develop therapies that target neurological conditions, rare genetic diseases, and immune-related indications, while pursuing collaborations and licensing arrangements to extend its reach and funding for development and commercialization. The firm maintains a corporate presence in the United States and conducts clinical and research activities globally, with headquarters in Foster City, California, and a founding year in 1995, positioning itself as a clinically oriented biotech with a mixed model of internal program advancement and external partnerships. Core products and services encompass: genomic medicine research and development; gene therapy product candidates; ex vivo gene-edited cell therapies; in vivo genome editing and genome regulation therapies; research and development services including preclinical and translational science; collaboration and licensing revenue from partnerships with larger pharmaceutical companies; regulatory and quality assurance activities supporting clinical trials; manufacturing and process development capabilities for gene therapy vectors and delivery platforms; and supportive diagnostic and biomarker activities to guide patient selection and trial design. Latest major company changes include strategic partnerships and licensing deals advancing neurology-centric programs, portfolio focusing on high-value neurology assets, and continued collaboration agreements with major pharma players; corporate restructurings or reorganizations aimed at refining the pipeline toward internal neurology programs while monetizing non-core assets through in-licensing or out-licensing arrangements; notable actions such as acquisitions or divestitures in adjacent capabilities, and leadership and organizational adjustments to align with a “neurology-first” strategy and capital efficiency objectives. Additional context indicates Sangamo operates in multiple industry segments including neurology, hematology/rare diseases, and broader genomic medicine platforms, targets a global patient population, and maintains subsidiary and partner relationships to extend development and commercialization capabilities.